Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
3(19%)
Results Posted
63%(5 trials)
Terminated
1(6%)

Phase Distribution

Ph phase_4
2
13%
Ph phase_2
7
44%
Ph not_applicable
2
13%
Ph phase_1
1
6%
Ph phase_3
2
13%

Phase Distribution

1

Early Stage

7

Mid Stage

4

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
1(7.1%)
Phase 2Efficacy & side effects
7(50.0%)
Phase 3Large-scale testing
2(14.3%)
Phase 4Post-market surveillance
2(14.3%)
N/ANon-phased studies
2(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

3

trials recruiting

Total Trials

16

all time

Status Distribution
Active(3)
Completed(8)
Terminated(1)
Other(4)

Detailed Status

Completed8
Recruiting3
unknown3
Suspended1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
3
Success Rate
88.9%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (7.1%)
Phase 27 (50.0%)
Phase 32 (14.3%)
Phase 42 (14.3%)
N/A2 (14.3%)

Trials by Status

suspended16%
recruiting319%
completed850%
terminated16%
unknown319%

Recent Activity

3 active trials
Showing 5 of 16
completedphase_2

Dopaminergic Dysfunction in Late-Life Depression

NCT04469959
recruitingnot_applicable

Study of L-dopa Treatment in Patients With a Neurodevelopmental Disorder (CTNNB1 Gene)

NCT07614126
recruitingphase_2

Etoricoxib in Patients With Parkinsonian Disease

NCT07370532
recruiting

Substance Abuse Pre-Treatment Screening Study

NCT00439049
unknownphase_2

Improving Therapeutic Learning for PTSD

NCT04558112
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT04469959Phase 2

Dopaminergic Dysfunction in Late-Life Depression

Completed
NCT07614126Not Applicable

Study of L-dopa Treatment in Patients With a Neurodevelopmental Disorder (CTNNB1 Gene)

Recruiting
NCT07370532Phase 2

Etoricoxib in Patients With Parkinsonian Disease

Recruiting
NCT00439049

Substance Abuse Pre-Treatment Screening Study

Recruiting
NCT04558112Phase 2

Improving Therapeutic Learning for PTSD

Unknown
NCT01770145Phase 4

Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)

Completed
NCT03761030Phase 4

L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults

Terminated
NCT04000919Phase 2

Effects of 5HTP and LDOPA on CNS Excitability After SCI

Suspended
NCT00537017Phase 2

Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175)

Completed
NCT03754062Phase 1

Pharmacological Modulation of Belief Salience

Completed
NCT03891095Not Applicable

Oxytocin and Dopamine's Effect on Vicarious Optimism

Completed
NCT00406029Phase 2

Dyskinesia in Parkinson's Disease (Study P04501)

Completed
NCT01646255Phase 3

Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients

Completed
NCT01504178Phase 3

Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease

Completed
NCT02578849

Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia

Unknown
NCT02347059Phase 2

L-dopa Versus Dopamine Agonists After Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease

Unknown

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16